On September 21, 2020 Light Chain Bioscience reported that it has achieved two milestones and received corresponding payments under its research and collaboration agreement with the LamKap Bio Group, Pfäffikon, Switzerland (Press release, Light Chain Bioscience, SEP 21, 2020, View Source [SID1234565460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration aims at developing bispecific antibodies capable of re-targeting T cells to tumor cells as well as blocking the immune checkpoint CD47 on the same tumors for the treatment of solid cancers. These milestones were achieved upon the successful completion of the discovery phase and designation by LamKap Bio of bispecific antibodies as clinical development candidates with approval to advance to IND-enabling studies and GMP manufacturing with its partner Lonza, Basel, Switzerland.

"It is very satisfying to have reached these first important milestones. This is the result of a truly collaborative effort. The successful identification of therapeutic bispecific antibody candidates harnessing different modes of action to kill tumor cells further validates our κλ body platform" said Nicolas Fischer, Light Chain Bioscience’s Chief Executive Officer. "We believe that the native human structure of these bispecific candidates represents a significant advantage for the treatment of patients."